SynthesisSexually transmitted infections2018
Prevalence of
Synthesis in Sexually transmitted infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Genital mycoplasma infection: a systematic review and meta-analysis.Reproductive health · 2023Pooled it
- Efficacy of azithromycin in treating Ureaplasma urealyticum: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Adverse pregnancy and perinatal outcomes associated withSexually transmitted infections · 2022Pooled it
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000-2019).BMC public health · 2020Pooled it
- Pooled it
- Pooled it
- Prevalence of five treatable sexually transmitted infections among women in Lower River region of The Gambia.BMC infectious diseases · 2023Trial
- Article
- Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance-Guided Therapy?The Journal of infectious diseases · 2026Article
- Antimicrobial resistance crisis in STIs: Gonorrhea andNew microbes and new infections · 2026Review
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Prevalence ofInfectious disease reports · 2026Article
- [Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance].Dermatologie (Heidelberg, Germany) · 2026Review
- The Role of Antimicrobial Susceptibility and Resistance Testing forOpen forum infectious diseases · 2026Article
- Predictors of self-reported sexually transmitted infections (STIs) among men in 54 low and middle income countries (LMICs): a comparison of deep learning and classical machine learning algorithms.BMC infectious diseases · 2026Article
- PreconceptionmedRxiv : the preprint server for health sciences · 2026Article
- Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Distribution and trends of the global burden of female infertility attributable to sexually transmitted infections from 1990 to 2021.BMC infectious diseases · 2026Article
- Towards precision management ofFrontiers in cellular and infection microbiology · 2026Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
resultsOf 3316 screened records, 63 were included. In randomly selected samples from the general population, the summary prevalence was 1.3% (95% CI 1.0% to 1.8%, I DISCUSSION: This systematic review can inform testing guidelines for REGISTRATION NUMBERS: PROSPERO: CRD42015020420.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.